One-on-One
Lukasiewicz; Weiss & Farber, MD, PhD; Bond Benton, PhD
Season 2026 Episode 2972 | 26m 46sVideo has Closed Captions
Sylvester P. Lukasiewicz; Debi Weiss & Charles Farber, MD, PhD; Bond Benton, PhD
Sylvester P. Lukasiewicz, Director, Back to One — Return to Ground Zero, discusses a survivor's deeply personal after returning to NYC more than two decades after 9/11. Debi Weiss, Lymphoma Survivor, & Charles Farber, MD, PhD, Hematologist-Oncologist at Atlantic Health, talk about Debi’s cancer journey. Bond Benton, PhD, Professor of Strat Comm at Montclair, examines social media algorithms.
Problems playing video? | Closed Captioning Feedback
Problems playing video? | Closed Captioning Feedback
One-on-One is a local public television program presented by NJ PBS
One-on-One
Lukasiewicz; Weiss & Farber, MD, PhD; Bond Benton, PhD
Season 2026 Episode 2972 | 26m 46sVideo has Closed Captions
Sylvester P. Lukasiewicz, Director, Back to One — Return to Ground Zero, discusses a survivor's deeply personal after returning to NYC more than two decades after 9/11. Debi Weiss, Lymphoma Survivor, & Charles Farber, MD, PhD, Hematologist-Oncologist at Atlantic Health, talk about Debi’s cancer journey. Bond Benton, PhD, Professor of Strat Comm at Montclair, examines social media algorithms.
Problems playing video? | Closed Captioning Feedback
Where to Watch One-on-One
One-on-One is available to stream on pbs.org and the PBS app.
Providing Support for PBS.org
Learn Moreabout PBS online sponsorship- [Narrator] Funding for this edition of One-On-One with Steve Adubato has been provided by EJI, Excellence in Medicine.
A New Jersey health foundation program.
The Adubato Center for Media Leadership.
Because media matters more than ever.
Valley Bank.
Newark Board of Education.
New Jersey Board of Public Utilities.
Providing New Jersey residents tools to save money on energy costs.
Robert Wood Johnson Foundation.
Working to create a future where health is no longer a privilege, but a right.
The North Ward Center.
PSEG Foundation.
And by New Jersey Sharing Network.
Promotional support provided by Meadowlands Chamber.
Building connections, driving business growth.
And by Insider NJ.
- This is One-On-One.
- I'm an equal American just like you are.
- The way we change Presidents in this country is by voting.
- A quartet is already a jawn, it’s just The New Jawn.
- January 6th was not some sort of violent, crazy outlier.
- I don't care how good you are or how good you think you are, there is always something to learn.
- I mean what other country sends comedians over to embedded military to make them feel better.
- People call me 'cause they feel nobody's paying attention.
_ It’s not all about memorizing and getting information, it’s what you do with that information.
- (slowly) Start talking right now.
- That's a good question, high five.
(upbeat music) - Hey, everyone, Steve Adubato.
This is part of our "Arts Connection" as well as our "Media Matters" series.
We're joined by our good friend, Sylvester Lukasiewicz, who is the founder of SPL Films and director of an important film called "Back to One - Return to Ground Zero."
Sylvester, good to see you, buddy.
- Hey, Steven.
Nice to see you too.
- Let me also disclose that Sylvester handles all the post-production on our sister series, "Lessons in Leadership."
"Back to One - Return to Ground Zero," talk about it, Sylvester.
- Steve, this story is familiar to many of us, especially New Yorkers and those who were there 25 years ago.
But Steven, the main character in the film, and I met shortly after 9/11 in film school in New York City and we've remained in touch.
And he, over the years, would disclose some information about what he did before we met.
And it turned out to be that he was one of the employees over at the Windows on the World, the restaurant that was on top of the World Trade Center.
And after he and I finished film school, he moved out of New York, he moved to LA to pursue his career.
And I remained in New York, but every year we would get on the phone around 9/11 and talk about these things that he kept inside of him.
And he wanted to come back every year as the Ground Zero was being rebuilt.
But for some reason he was not able to.
He was really struggling with that idea.
And so, it took some years, but finally last year in 2024, he and his wife decided to come to New York and visit the rebuilt Ground Zero.
And so, it has been a long journey to actually making this film, which was never a film to begin with.
It really happened very sporadically, very spontaneously, the day before they arrived.
So in the long run, it's really a beginning of a process of dealing and coping with something that happened a long time ago, but very effectively, I think, because it tells a very different story, different story of 9/11 than those told for the past 25 years, the typical 9/11 stories and recounts.
For Steven, it's a very important journey.
And for myself, it was also in a way, a tool to kind of revisit that day and those days after because I myself was there that day.
It's also very, very internal of a story.
It's something that we've been carried for all these years.
And by him coming to New York and being in that space, in that area that he remembered so vividly, it brought back a lot of memories, a lot of internal feelings and emotions.
And so, it's a different film.
It's a different story.
I wouldn't even call it a film.
It's really just a journey, almost like a walk with a friend and hearing and listening.
- Where can people find it?
- So the film has been making film festival circuit for the couple of months now.
It had a premiere in New York City area on 9/11, this past 9/11, the 25th anniversary on two channels on NYC Life and CUNY TV.
And it also broadcast in Poland.
I was born in Poland.
I have a close connection to my country.
And so there was a strong interest in showing that story, a different story of 9/11 on that big 25th anniversary.
And it was very well received in press and in print and in radio.
So it is going to be nationally syndicated starting January of next year on public television stations around the country, including PBS.
So it'll be also streaming on PBS app.
So I hope that it'll reach wider, even wider audience and those who wish to see it.
Why does film matter so much?"
Got two minutes left.
- It's a magical medium, Steve.
It tells emotions, it tells experiences, it tells things that cannot be told in any other way.
A lot of people can't access those places that they would like to go to or speak to someone or hear someone who is long gone.
I think recording history is such a big job and also responsibility of a filmmaker, journalist to have a record for the future, for those who will be seeking, will be looking back in time and saying, "Hey, there was this story, there was this guy.
He was a singular out of many that worked in that place and he has this tremendous story of telling, retelling."
And so, I think media is still very important.
I think public media is, it's really, really charged with heavy, heavy responsibility.
And I think this being a very different storytelling in a form of a film will really come across to many, young, old and beyond.
- Sylvester, I want to thank you.
Film does matter.
Media does matter.
And we wish Steven, who is featured in this film that Sylvester directed, produced, edited, made happen, we wish him and his family all the best.
Sylvester, thank you, my friend.
You're a great partner and teammate and colleague.
And as we like to say, a leader in media and it matters now more than ever.
Thank you.
Take care, Sylvester.
- Thank you, Steve.
Take care.
- You got it.
Stay with us, we'll be right back.
- [Narrator] To watch more One on One with Steve Adubato find us online and follow us on Social media.
- Welcome back, folks.
We're going to be talking about CAR T-cell therapy with two people who know it from different perspectives, but know it well.
Debi Weiss is a lymphoma cancer survivor, and Dr.
Charles Farber is a hematologist and oncologist at Atlantic Health.
Full disclosure, Atlantic Health is one of our healthcare underwriters.
Great to have you with us.
Debi, talk to us.
I'm sorry for interrupting.
Back in January of 2024, you thought you had the flu.
It was not the flu.
- No.
- Talk to us.
- So I didn't feel well.
I though it was the flu.
Like everything else, I figured it would just go away.
It turned out that I got sicker and sicker and wound up being diagnosed with large B-cell lymphoma.
- Dr.
Farber, when you first met Debi, how clear was it to you what she was dealing with?
- Well, it was suspected, not entirely clear.
Debi had, as I recall, seeing her for the first time in the emergency department, a very large mass in her left neck.
She appeared to me to be chronically ill, had lost weight, wasn't eating well.
So we needed to take the next step, the gold standard, and that's obtain a biopsy and a true diagnosis.
- And Debi, did you go through chemotherapy?
- Yes.
- How effective was it?
- I thought it was really effective.
I did two rounds of chemo while in the hospital, four rounds as an outpatient.
And when those were finished, I actually thought I was done and was going to be able to resume my life.
- And Dr.
Farber, what was really going on and where does CAR-T cell therapy come into the equation for Debi?
- Sure thing.
I agree with Debi.
She did fabulous.
She achieved a complete remission, but unfortunately complete remissions are not equatable with cures.
And as I recall, about one or two months after completing her therapy, being in remission, she developed some neurologic issues.
So unfortunately, she had recurred in her brain.
There's something called- - One second.
I'm sorry for interrupting.
Debi, you were having severe headaches, correct?
- Yes.
- Okay.
I'm sorry for interrupting, doctor.
Go ahead.
- No, that's okay.
She presented, I think she had some confusion as well as the significant headaches.
And on further investigation imaging, we found that she had a large mass within her cranium.
Biopsy revealed a recurrence.
There's something called the blood-brain barrier.
So the chemotherapy you give in the vein doesn't penetrate the brain.
It's a sanctuary and unfortunately, it weathered the earlier chemotherapy.
So she had recurred.
- First of all, what is CAR T-cell therapy A and B?
How does it become the protocol for Debi in this particular case?
- Sure.
So CAR T is an acronym.
It stands for chimeric antigen receptor T-cells.
It's a medical technology or procedure we do.
It's mostly used currently for patients with relapsed refractory hematologic malignancies, such as Debi had diffuse large B-cell lymphoma, but also multiple myeloma, acute lymphoblastic leukemia.
And now we're even using it in autoimmune disorders.
At any rate, what this involves is collecting a subset of white blood cells from the patient, Debi.
We ship them to a facility, a special laboratory that genetically modifies.
It engineers Debi's own cells, the patient's own cells to do what those cells had not been able to do earlier, eliminate the cancer.
The cells, after they're genetically modified and expanded in terms of the numbers of them are shipped back to the treating physicians here at Morristown Medical Center.
And then we prepare Debi and give her her own cells back that have been modified in such a way that they're now very active against this cancer.
- Before I come back to Debi, Doctor, how long has CAR T-cell therapy been around?
- Well, it was first developed in the early 2010s, was pioneered at University of Pennsylvania, but it's come into more widespread use the last three or four years, and it's a very exciting technology.
- Debi, what was your response to the CAR T-cell therapy?
- In terms of my health or in terms of my emotional?
- Well, you can go wherever you want with it.
- Okay.
So I looked at all of the information that Dr.
Farber gave me and realized this was something I wanted to do.
I was extremely fortunate.
I went through this without very many side effects at all, and it was pretty fascinating.
Being a person who is very interested in the body and biology, I found it to be one of the most interesting things.
It was almost like they gave me my cells back and they were like little Pac-Men and they just went in and did their job and I'm fine.
- When you say you're fine, the tests, several months after, I believe three months after, the scans showed no sign of cancer?
- Correct.
- Doctor, so help us understand this.
When the test came back that there was no sign of cancer, that Debi did not have any signs of cancer, was the cancer cured, Doctor?
- Unfortunately, only time can say that a patient's cured, but she is in a complete clinical remission.
There's no evidence of disease.
Her clinical status has improved to the point that she's at her baseline where she was perhaps a couple years ago.
- Sure.
- So she's doing fabulous from my perspective.
- And Debi, from your perspective, describe your life style.
- I'm a pretty active person.
So prior to being diagnosed with lymphoma, I was a very healthy 70-year-old woman that just happened to be diagnosed with cancer.
Since the CAR T, my life has gone back pretty much to where it was before.
I'm working, I'm a Pilates teacher and I work in a retail store part-time.
I walk.
Unfortunately, I recently had an accident, so I fell and broke my wrist and my hip, but that's being dealt with on a different level.
I truly believe that I will be fine.
- You're a Pilates instructor?
- Mm-hmm.
- I've been doing it for 10 years.
Why can't I figure out the Reformer?
(all laughing) I'm sorry.
Doctor, before I let you go, how about people are wondering right now, who is a candidate for CAR T-cell therapy and who is not, Doctor?
- Sure.
Well, it casts a wide net that most patients who require it are appropriate.
So certainly for patients with many of the hematologic malignancies who recur sort of early on after their initial remission or those who don't achieve a complete remission to start off with.
So widespread, we're using it for diffuse large B-cell lymphoma, multiple myeloma and ALL, but also autoimmune diseases, we're branching out and it's being used for non-malignant conditions.
Lupus, I'm sorry.
- No, no.
Doctor, not cheap though.
- No, it is expensive.
We tend not to focus on that, but you're absolutely correct.
These technologies come at a cost, but this is a tremendously beneficial technology and it fulfills an unmet need.
So Debi would not have been in very good shape with the other conventional treatments for her condition.
So you are correct.
It is pricey and fortunately insurance for most patients does cover it because it's so effective.
- Medicine is pricey, but important.
Debi, 30 seconds.
Advice for others.
- My biggest advice, and I say this all the time, is you have to have faith in your doctors and your medical team.
So I met Dr.
Farber at the very beginning of my journey.
He has taken me from being extremely sick to being extremely healthy and I trust him implicitly.
So if you don't have that kind of faith in your medical team, find another medical team.
- Debi, wish you all the best.
Thank you for joining us.
Dr.
Farber, thank you as well.
And all good things.
- Thank you.
- That's what we wish you, Debi.
- Thank you so much.
- Thank you.
- You got it.
Stay with us, we'll be right back.
- [Narrator] To watch more One on One with Steve Adubato find us online and follow us on Social media.
- We continue our series, "Media Matters" with a scholar over at Montclair State University, Dr.
Bond Benton, who's Professor of Strategic Communication at Montclair State University's College of Communication and Media.
Bond, good to see you.
- Good to see you.
- Talk to us about your specialty in social media, Why you're interested in social media, and what should be our greatest concern right now?
- I am in public relations, and one of the things that I studied a little over a decade ago was just how powerful social media was, particularly in getting a brand's message out, but what I kind of discovered, most unfortunately, was that the same infrastructure that gets a brand's message out can get terrible information out, and that infrastructure that rewards terrible information is something that we, as concerned citizens, parents, educators, and members of the community, really, really have to be aware of.
- Professor, you've said that social media is not a neutral space.
What do you mean by that?
- Social media rewards bad content.
There is an algorithm that is competing for people's attention.
What consistently gets people's attention more is terrible things.
So you're gonna see awful content in social media.
They're gonna amplify it, because that's the sort of thing that will get the clicks, right?
If you see something adorable and charming, you'll kind of smile and move on, but if you see something that offends you, you're gonna click on it and get engaged.
They recognize that, and they really monetize the use of terrible content to make people stay on platforms.
- Let me push back a little bit in this way.
- Sure.
- It's not even pushing back.
It's trying to understand this.
I have an ongoing discussion with our team about how we use social media, and it's like, "Steve, we need more social media engagement.
We need more digital engagement."
All that's true, because underwriters and sponsors want to see what's your digital engagement, and I often wonder a conversation like this, Professor Benton, conversation like this, policy-oriented, somewhat intellectual, hopefully, accessible and relatable to folks, not gonna kill it on the clicks, is it?
- No, it's not, and that is... You know, I think that there's the old quote that was attributed to Mark Twain that, you know, the truth will, by the time truth gets its pants on, you know, the lie has ran halfway across the world, and, yeah, it's not that... There's a kind of take-your-medicine quality to it as well.
I had thought, previously among young people, some of the criticisms of social media sounded like some of the antique criticism of like rock and roll and comic books, you know, "Oh, the media that the kids are on, it's really, really bad."
It's just sort of maybe we cried wolf too many times as researchers.
Social media is, objectively, like it has pretty harmful effects, unlike other kind of like moral panics about previous youth-oriented media.
- This is different.
- Yeah.
- That's what you're saying.
- Yeah.
- You're saying when Elvis Presley came out.
- Exactly.
- And the networks would not show him below his waist, because it was somehow scandalous or The Beatles, the whole bit, well, rock and roll, it was gonna destroy our kids' mind, whatever.
You're saying social media is different.
- Yeah, social media is distinct.
I think that there was a lot of, you know, sort of overstated things, yeah, like heavy metal's gonna make kids deliver worshipers.
They shouldn't play Dungeons and Dragons.
All of this was really baseless moral panics, but with social media, we're getting an inkling of some of the data around it, and, objectively, it's a problem.
One of the studies that I did was on the Buffalo mass shooter, Payton Gendron, and the manifesto that he released prior to the mass shooting.
We did, with a co-author, a forensic analysis of that manifesto, and what we discovered was that there was a very predictable pattern to his internet engagement that took him from kind of sketchy places online to, objectively, evil places online in pretty short order, and, you know, that's just one study we did.
There's documentation that, you know, women engaging with Instagram and with a lot of frequency, they're gonna be more likely to have disordered eating because of that.
There is like quality data out there that shows social media has pretty harmful effects when consumed in an unhealthy fashion.
- Devil's advocate, can't stop it.
- No.
- Can't stop it.
Someone says, "Yeah, well, the professor's concerned.
He's done this research, it's dangerous, but everyone has a right to use social media as they choose to."
How the heck are we gonna regulate it differently, manage it differently?
What advice do we have for parents?
It is what it is, isn't it?
Or am I missing something?
- No, absolutely, you're not missing anything, and there is no regulatory framework that's gonna be successful.
A researcher that I've worked with pretty extensively has studied something called the Digital Services Act in the European Union, which sought to regulate some of the structures of social media.
You know, I think it's well intentioned.
It hasn't really done anything.
- Enforceable?
- What's that?
- Enforceable?
- Not enforceable, and it shouldn't be in some ways, and it is going to really come down to a lot of things.
I think that consumer advocacy is going to be a big part of it, that we are going to have to, as consumers, start to make some choices that if we see a platform that just is continually giving us content, that we can see that it's not making our lives better, maybe making us scared, maybe, you know, giving us problematic information, then we're gonna have to maybe say that, "Enough with that platform," and that's gonna be part of it.
Parents' education will be another big part of it as well.
You know, I don't know about the specifics of the legality, but the recent judgment against Meta related to youth harms and social media, it's not sort of dissimilar to early, the lawsuits against the tobacco industry that, you know, we started with cigarettes are cool, and James Bond smokes them, but, you know, over time, people started to say, "Maybe there's a pretty negative consequence to this."
If we're maybe kind of getting an awareness of that, that the hope for self-regulation, I think is gonna only come when the market demands it, and we're part of the market.
- But, Bond, if (sighs) it's playing with our minds, if the algorithm knows how to mess with us, and not me, it's just anyone.
- Yeah.
- But there are certain things I'm drawn to, but if someone's mind is caught up in cat videos, dog videos, little baby videos, which harmless, right?
It plays with our mind.
I guess it's called dopamine.
I don't totally understand it.
What do you mean self-regulate ourselves if something's happening to the chemicals in our brain?
- As far as what you've just described, I wouldn't have any problem with that.
- That's not the problem.
- Oh, no, no, no.
- That's not the problem.
- And I follow a certain sports team that I think most people in your viewership would despise this sports team, but you know, I'll watch- - Who is it?
The Chiefs.
I'm from Kansas City originally.
- All right, we can end the interview right now.
- Okay, I figured as much.
- I'm Patrick Mahomes fan.
Go ahead, I'm sorry.
- Oh, yeah.
I would totally get with that, but, you know, I'll read, you know, fake injury reports all the time, and, you know, I know that the infrastructure that gives me those fake injury reports are the same ones that give anti-vaccination information, too, right?
Like we he need to click more.
- That's dangerous.
- Right, yeah, exactly, and I think that, you know, the ability to make that distinction between sort of harmless clicking on content to relieve boredom, I mean, it's not a lot worse than watching, you know, like the least objectionable television show in the 1970s and '80s, and everybody did that for years.
So I mean, I don't think that there's anything, you know, problematic about that, but there is some legitimate content out there that really makes people more vulnerable, and it could be dangerous.
- Dr.
Bond Benton, who's Professor of Strategic Communication at our higher ed partners at Montclair State University's College of Communication Media.
Hey, Bond, thank you so much for joining us.
- Thank you so much.
- We appreciate it.
- For having me, and thank you for bringing this issue up.
It's just essential we talk about it.
That's got to be the important first step, and thank you so much for taking that step.
- Will not be the last conversation.
I'm Steve Adubato, that is Professor Benton.
We'll see you next time.
- [Narrator] One-On-One with Steve Adubato is a production of the Caucus Educational Corporation.
Funding has been provided by EJI, Excellence in Medicine.
A New Jersey health foundation program.
The Adubato Center for Media Leadership.
Valley Bank.
Newark Board of Education.
New Jersey Board of Public Utilities.
Robert Wood Johnson Foundation.
The North Ward Center.
PSEG Foundation.
And by New Jersey Sharing Network.
Promotional support provided by Meadowlands Chamber.
And by Insider NJ.
- Are you looking to be a part of a dynamic, forward-thinking business service organization?
At Meadowlands Chamber, every day we connect, collaborate and innovate, helping to drive business and economic growth in the greater Meadowlands and New Jersey.
I invite you to visit our Meadowlands Chamber headquarters, an open office facility with access to resources for our members' businesses and networking needs.
Together, we will build the chamber of the future, and the next generation of leaders.
Back to One — Return to Ground Zero: Loss and healing
Video has Closed Captions
Clip: S2026 Ep2972 | 7m 18s | Back to One — Return to Ground Zero: Loss and healing (7m 18s)
Cancer survivor & doctor discuss her transformative journey
Video has Closed Captions
Clip: S2026 Ep2972 | 10m 55s | Cancer survivor & doctor discuss her transformative journey (10m 55s)
Why social media rewards negative content
Video has Closed Captions
Clip: S2026 Ep2972 | 9m 2s | Why social media rewards negative content (9m 2s)
Providing Support for PBS.org
Learn Moreabout PBS online sponsorship
New Episode- News and Public Affairs

Top journalists deliver compelling original analysis of the hour's headlines.
New Episode- News and Public Affairs

Today's top journalists discuss Washington's current political events and public affairs.


New Episode
New Episode
New Episode
New Episode

New Episode


Support for PBS provided by:
One-on-One is a local public television program presented by NJ PBS



